Biotest AG

  • WKN: 522723
  • ISIN: DE0005227235
  • Land: Deutschland

Nachricht vom 05.09.2019 | 07:00

Biotest AG: Biotest Achieves Important Clinical Milestone for IgG Next Generation

DGAP-News: Biotest AG / Key word(s): Research Update

05.09.2019 / 07:00
The issuer is solely responsible for the content of this announcement.


/
PRESS RELEASE

Biotest Achieves Important Clinical Milestone for IgG Next Generation

- Phase III study in Primary Immune Thrombocytopenia (ITP) completed, data evaluation in progress, promising results

- The study is one of two pivotal phase III studies in the clinical program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G

- Clinical development in line with progress of new manufacturing facility Biotest Next Level


Dreieich, 5 September 2019. Biotest AG today announced the completion of study no. 992 - a phase III study investigating IgG Next Generation as immunomodulatory therapy in patients diagnosed with chronic primary immune thrombocytopenia (ITP). ITP is an autoimmune disease in which the immune system attacks and destroys the body's own platelets, the cells that prevent bleeding in blood vessels and facilitate clotting. In the study 34 patients were treated. The evaluation of data is ongoing. First results confirm efficacy and safety expectations.

"We are very pleased to have completed the first key program milestone in the development plan for our new intravenous immunoglobulin. Final results are expected end of Q4/2019", said Jörg Schüttrumpf, Head of Corporate R&D. "This product will be a new generation of our polyvalent immunoglobulin portfolio."

Study no. 992 is one of two pivotal phase III studies in the clinical program for IgG Next Generation. After finalization of the second trial with IgG Next Generation in Primary Immunodeficiency (PID), both studies will be submitted together to the health authorities. Following approval, IgG Next Generation can be marketed in additional established indications of intravenous immunoglobulins, in particular replacement therapy in secondary immunodeficiency disease (e.g. chronic lymphocytic leukaemia, multiple myeloma, after allogeneic haematopoietic stem cell transplantation) and as immunomodulatory therapy in Guillain Barré Syndrome (GBS), Kawasaki disease, Multifocal motor neuropathy (MMN) and Chronic inflammatory demyelinating polyneuropathy (CIDP). The sales potential of immunoglobulins in immunomodulatory diseases in Europe is in the range of EUR1.3 billion, 7% thereof in ITP itself.

IgG Next Generation is manufactured using an innovative production process and will be the master product of the new Biotest Next Level manufacturing facility currently under construction. This new manufacturing facility, which uses state of the art technologies, represents Biotest's latest commitment to the global immunoglobulin markets.

About study no. 992
Study no. 992 is a phase III, open label, prospective, multicentre trial investigating the clinical efficacy and safety of IgG Next Generation as immunomodulatory therapy in adult patients diagnosed with chronic primary immune thrombocytopenia (ITP) at high risk of bleeding or before surgery to correct the platelet count.
Patients are randomized in a 1:1 ratio to receive either 1 g/kg bodyweight per day for 2 consecutive days or 0.4 g/kg bodyweight per day on 5 consecutive days. The primary objective of this study is to determine the percentage of patients who achieve response. A response is defined as a platelet count of >=30×109/L and at least a 2-fold increase of the baseline count and the absence of bleeding.
More information about the study design can be found at www.clinicaltrialsregister.eu (EudraCT Number: 2015-003653-17)

About Primary Immune Thrombocytopenia (ITP)
Primary immune thrombocytopenia - also formerly known as idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura - is an autoimmune-mediated condition, in which autoantibodies with specificity for one or more platelet membrane glycoproteins (GPs), binds to circulating platelet membranes. The coating of platelets with autoantibodies renders them susceptible for elimination from the blood.
Because patients suffering from ITP have a low platelet count, they may bruise easily and experience bleeding that is hard to stop. ITP is a rare blood disorder that affects about five to nine in 100,000 adults each year.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematosus, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,700 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.


IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



05.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktuelle Research-Studie

ITM Power PLC

Original-Research: ITM Power Plc (von First Berlin Equity Research GmbH): Hinzufügen

15. Oktober 2019